I am looking forward to moderating tomorrow's MassTLC panel on R&D IT Best Practices for Growing Small/Mid-Sized Biopharmas in Microsoft's New England R&D Center in Cambridge. It's a great group of panelists, so this event should be a lot of fun.
If you haven't already done so, please register for the event at https://bit.ly/9gUR4p.
Here are the biographies of the panelists:
David Osterman is Director of Research Informatics at Biorelix, Inc., a pharmaceutical firm developing anti-infective therapeutics that target microbial riboswitches. Prior to BioRelix, he was a Consultant and Research Fellow at The Schooner Group, LLC. During a distinguished career at Bayer Healthcare, Osterman was a Research Fellow, directing a senior level science & technology innovation group. He played a key role in developing Bayer’s approaches to assay development, small molecule screening, and informatics. He also led one of Bayer’s auto-immune therapies research groups. Osterman holds a Ph.D. from the University of Chicago, and he completed postdoctoral studies at the University of California, San Francisco and at Rockefeller University.
Tom Plasterer is an Adjunct Professor in Northeastern University’s Department of Chemistry and Chemical Biology. In this role, he utilizes correlation network approaches in a study of plant bioreactor systems for producing anti-cancer therapeutics. In the commercial arena, Tom held a range of roles at Beyond Genomics, including Principal Scientist - Bioinformatics and, most recently, Director of Project Planning and Data Interpretation. Tom earned his Ph.D. in Pharmacology from Boston University.
Keith Robison is a scientist and bioinformatician. He is Lead Senior Scientist at Infinity Pharmaceuticals, where he applies cancer genomics information to clinical and pre-clinical small molecule oncology efforts and manages outsourcing relationships with genomics vendors. Among several past roles, he has been a Principal Scientist at Codon Devices and a Senior Scientist at Millennium Pharmaceuticals. He is the author of the popular “Omics! Omics!” blog, and he earned his Ph.D. in Molecular & Cell Biology from Harvard University.
Jeff Warhaft is the Associate Director of R&D IT Solutions Delivery at Biogen Idec. Prior to joining Biogen Idec, he held several roles at Keane, Inc., a large technology and business process consultancy. At Keane, his roles included Senior Principal Consultant and Principal Consultant. Mr. Warhaft earned a Masters of Health Administration from the University of Ottawa, and he holds Bachelor of Science in Biomedical Engineering from Rensselaer Polytechnic Institute.
Barry Wythoff is a scientist and IT Project Manager at Ironwood Pharmaceuticals, Inc., where he is responsible for coordinating key R&D IT initiatives. His career has seen him make contributions to the chemistry and cheminformatics efforts of a diverse range of firms, including Avila Therapeutics, Astra Zeneca, Biogen IDEC, ArQule, Millennium Pharmaceuticals, Inc., and Eastman Kodak. He also owns a consulting business, Scientific Reasoning. Barry earned his Ph.D. in Analytical Chemistry from the University of New Hampshire.
David Yee is the Head of Knowledge & Information Systems at Archemix Corporation, a privately-held biopharmaceutical company that aims to develop aptamers as a new class of directed therapeutics for the prevention and treatment of chronic and acute diseases. Prior to joining Archemix, Dr. Yee was an Associate Director at Millennium Pharmaceuticals, and a Bioinformatician at ZymoGenetics. He also serves as a member of the Massachusetts Technology Leadership Council’s Life Sciences Advisory Board. He earned his Ph.D. from the University of California, San Francisco.